Professional Documents
Culture Documents
John Craighead, PhD, Managing Director, Investor Relations & Business Development, BIO
June 29, 2011 2:00PM - 3:30PM Room: Level 1, 147 AB
Overview
Forward looking dealmaker intentions
Analysis of one-on-one partnering meetings held in the 2011 BIO Business Forum
What assets are in the highest demand by pharma/in-licensors?
2
Non-profit
16%
11%
9% 4%
other
19%
R&D
59%
Drug Out-licensors
n = 717
PII 33%
PI 16%
81%
n=2400
n=890
n=717
4
8 6 4 2 0
6.1 4.1
2010
2011
n=173
5
250
NUMBR OF COMPANIES
200 150
100 50 0 3
8
6
PC PI M
PII
PIII
Womens Health
NUMBR OF COMPANIES
Dermatology
PC
PC PII PI PIII
2010 2011
PII
PI
Infectious Disease
Oncology
CNSPIII M
0 2 4 6 8 10 12 14 16 18 20 22 24
# of Companies
120
100 80 60
2010 2011
40 20
0
120 100 80 60 40 20 0 3 4 5 6 7
Vaccines
Respiratory
Oncology
CNS
Imunology ID CV
Derm
Metabolic
10 11 12
10
120 100 80 60 40 20 0 3
2011 2010
Oncology
Oncology
CNS CNS
Imunology
Metabolic
10
11
11
2011
GI CNS Immunology Metabolic Infectious Disease Oncology Dermatology Respiratory CV Vaccines
2011
GI CNS Immunology Metabolic Infectious Disease Oncology Dermatology Respiratory CV Vaccines
Alan F. Eisenberg Executive Vice President, Emerging Companies & Business Development
John Craighead, PhD Managing Director, Investor Relations & Business Development Cartier Esham, PhD Director, Emerging Companies Health & Regulatory Affairs
Wesley Triplett Director, BD Marketing Bernadette Blake Manager, Registration & Customer Service Renae Grant Manager, Partnering Programs Joe Colangelo Senior Manager, Business Development
Jen Welch, CMP Director, Meetings & Operations Celia Economides, MPH Manager, IR & Corporate Strategy
Fred Zeldow Director, Business Development & Strategic Alliances Tamy Dalal Manager, BD & Strategic Alliances Elizabeth Gaskins Manager, Membership